Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation

Peter W. Schreiber¹, Heike A. Bischoff-Ferrari², Katia Boggian³, Marco Bonani⁴, Christian van Delden⁵, Natalia Enriquez⁶, Thomas Fehr⁷, Christian Garzoni⁸, Hans H. Hirsch⁹, Cédric Hirzel¹⁰, Oriol Manuel¹¹, Pascal Meylan¹², Lanja Saleh¹³, Maja Weisser¹⁴, Nicolas J. Mueller¹*, the Swiss Transplant Cohort Study (STCS)¹⁵

¹ University Hospital Zurich and University of Zurich, Division of Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland, 2 University Hospital Zurich and University of Zurich, Department of Geriatrics and Aging Research, Zurich, Switzerland, 3 Cantonal Hospital St. Gallen, Division of Infectious Diseases and Hospital Hygiene, St. Gallen, Switzerland, 4 University Hospital Zurich and University of Zurich, Department of Nephrology, Zurich, Switzerland, 5 University Hospitals Geneva and University of Geneva, Department of Surgery, Service of Transplantation, Geneva, Switzerland, 6 Cantonal Hospital Chur, Internal Medicine, Chur, Switzerland, 7 Bern University Hospital (Inseelspital), Department of Infectious Diseases, University of Bern, Bern, Switzerland, 8 University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland, 9 University Hospital (CHUV) and University of Lausanne, Infectious Diseases Service, Lausanne, Switzerland, 10 University Hospital Zurich, Institute of Clinical Chemistry, Zurich, Switzerland

*nicolas.mueller@usz.ch

Abstract

Bone disease contributes to relevant morbidity after solid organ transplantation. Vitamin D has a crucial role for bone metabolism. Activation of vitamin D depends on the endocrine function of both, liver and kidney. Our study assessed key markers of bone metabolism at time of transplantation and 6 months after transplantation among 70 kidney and 70 liver recipients. In 70 kidney recipients 25-OH vitamin D levels did not differ significantly between peri-transplant (median 32.5nmol/l) and 6 months post-transplant (median 41.9nmol/l; P = 0.272). Six months post-transplant median 1, 25-(OH)₂ vitamin D levels increased by >300% (from 9.1 to 36.5ng/l; P<0.001) and median intact parathyroid hormone levels decreased by 68.4% (from 208.7 to 66.0 ng/l; P<0.001). Median β-Crosslaps (CTX) and total procollagen type 1 amino-terminal propeptide (P1NP) decreased by 65.1% (from 1.32 to 0.46ng/ml; P<0.001) and 60.6% (from 158.2 to 62.3ng/ml; P<0.001), respectively. Kidney recipients with incidental fractures had significantly lower levels of 1, 25-(OH)₂ vitamin D at time of transplantation and of intact parathyroid hormone 6 months post-transplant. Among 70 liver recipients, 25-OH vitamin D, 1, 25-(OH)₂ vitamin D and intact parathyroid hormone levels were not significantly altered between peri-transplant and 6 months post-transplant. Contrary to kidney recipients, median CTx increased by 60.0% (from 0.45 to 0.72 ng/ml; P = 0.002) and P1NP by 49.3% (from 84.0 to 125.4ng/ml; P = 0.001) in the longitudinal course. Assessed biomarkers didn’t differ between liver recipients with and without fractures. To conclude, the assessed panel of biomarkers proved highly dynamic after liver as well as kidney transplantation in the early post-transplant period. After kidney
transplantation a significant gain in 1, 25-(OH)$_2$ vitamin D combined with a decline in iPTH, CTx and P1NP, whereas after liver transplantation an increase in CTx and P1NP were characteristic.

Introduction

Solid organ transplantation is an established treatment for patients with end-stage renal failure or liver insufficiency. In the US more than 19,000 kidney and 7,000 liver transplantations were performed in 2016 [1]. Bone disease and resulting fractures are an important co-morbidity in patients with end-stage organ disease [2, 3].

In fact, it has been shown that the majority of liver recipients has abnormal bone mineral density (BMD) already at time of transplantation or has suffered from fractures pre-transplant [2, 4]. This may be explained by excessive alcohol consumption in some of these patients [5], but hyperbilirubinemia [6], hypogonadism [7] and reduced insulin-like growth factor-1 levels [8] may also contribute to abnormal bone metabolism. Among patients with end-stage renal failure, bone health is impaired with renal osteodystrophy presenting either as osteitis fibrosa, osteomalacia, adynamic bone disease or a mixed type [9, 10]. Consequently, both kidney and liver transplant patients have been found to have a high risk of bone loss and fractures [11, 12].

Bone mineralization depends on adequate calcium and phosphate levels [13, 14]. Two pivotal hormones regulating these minerals are 1, 25-(OH)$_2$ vitamin D (1, 25-(OH)$_2$D) and parathyroid hormone (PTH). The most important source of vitamin D is synthesis in the epidermis via ultraviolet B exposure. Vitamin D undergoes a first hydroxylation at the 25-position in the liver resulting in 25-OH vitamin D (25-OHD). 25-OHD is still a precursor of the active hormone, but due to its long half-life of 2 to 3 weeks it best reflects vitamin D status [15]. The circulating active hormone, 1, 25-(OH)$_2$D, emerges from 25-OHD via an additional hydroxylation at the 1-position in the kidney. 1, 25-(OH)$_2$D increases calcium levels not only by stimulation of intestinal calcium resorption but also in corroboration with PTH by increased renal resorption and mobilization out of bone tissue. Furthermore, 1, 25-(OH)$_2$D increases intestinal phosphate absorption and decreases phosphate excretion via the kidneys. Main drivers for production of 1, 25-(OH)$_2$D are PTH or hypophosphatemia, whereas calcium, fibroblast growth factor 23 and the active hormone 1, 25-(OH)$_2$D itself are inhibitory [13, 16]. PTH excretion is suppressed by 1, 25-(OH)$_2$D and a greater calcium intake [17].

Despite the substantial morbidity caused by impaired bone health among transplant patients, detailed data on bone metabolism changes after kidney or liver transplantation—both key organs of vitamin D hydroxylation—is limited. In the current study we used prospectively collected samples for measurements of vitamin D metabolites (25-OHD, 1, 25-(OH)$_2$D), intact PTH (iPTH), creatinine and two bone turnover markers, β-Crosslaps (CTx) and total procollagen type 1 amino-terminal propeptide (P1NP), in the same patients at time of transplantation and 6 months after transplantation. In line with recent recommendations CTx was used as parameter for bone resorption and P1NP for bone formation [18, 19]. We additionally reviewed all medical records for dual energy x-ray absorptiometry (DXA) scans performed, incident fractures recorded during post-transplant routine care, and supplementation of vitamin D and calcium.
Materials and methods

Study design, population and patient-related data

This study was a nested project within the Swiss Transplant Cohort Study (STCS, www.stcs.ch). Since May 2008 data on all solid organ transplants carried out in Switzerland have been prospectively collected in the STCS database [20]. All Swiss transplant centers, i.e. Basel, Bern, Geneva, St. Gallen, Lausanne and Zurich, contribute to data acquisition. The STCS was approved by the Ethic Committees of all participating institutions, i.e. Ethikkommission Nordwest- und Zentralschweiz EKNZ, Ethikkommission Bern, Ethikkommission Genf, Ethikkommission Ostschweiz EKOS, Ethikkommission Zürich. None of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given”. Information about vitamin D supplementation, calcium supplementation, BMD measurements and incidence of fractures were retrospectively collected by patient chart review, whereas all other data derived from prospective records. DXA scans to determine BMD were performed at the discretion of the treating physician. All fractures were radiographically confirmed. 70 kidney and 70 liver recipients were analyzed. Kidney transplantations and liver transplantations were performed between 05.05.2008 to 28.09.2009 and between 16.05.2008 to 20.12.2009, respectively. Median follow up was 5.6 years (IQR 5.5–5.8 years) in kidney recipients and 4.9 years (IQR 4.6–5.4 years) in liver graft recipients. For the subgroup analysis of female transplant recipients a simplified age-based approach was chosen to define menopausal status [21].

Laboratory analysis

For laboratory analyses prospectively collected citrate plasma samples, drawn at the time of transplant and 6 months post-transplant, which were stored at -80˚C in the STCS biobank. These samples were retrieved from the STCS biobank for centralized, uniform measurement at the Institute of Clinical Chemistry of the University Hospital Zurich. 25-OHD measurement was performed with Roche Diagnostics Vitamin D total assay on Cobas 8000 (Roche Diagnostics, Mannheim, Germany). Vitamin D status was categorized as follows: 25-OH vitamin D < 25nmol/l severe deficiency, 25 and < 50nmol/l deficiency and 50nmol/l no deficiency.

1, 25-(OH)₂D was determined with IDS-iSYS 1, 25-Di(OH)D on IDS-iSYS Multi-Discipline Automated System (Immunodiagnostic Systems Holdings PLC, Tyne and Wear, United Kingdom).

Intact PTH, CTx and total P1NP were measured using Roche Diagnostics Elecsys PTH (1–84) test, β–Crosslaps/serum and total P1NP on Cobas 8000 (Roche Diagnostics, Mannheim, Germany), respectively.

Creatinine was determined with a kinetic color test based on Jaffe Method from Roche Diagnostics (Mannheim, Germany) running on Cobas c701 system. Estimated glomerular filtration rate (eGFR) was calculated according to the CKD-EPI method [22], as this method was shown to provide more reliable results after liver transplantation [23].

Phosphate concentrations in plasma samples was measured using Roche Phosphat Molybdate assay (PHOS2) running on Cobas 8000 System (Roche Diagnostics, Mannheim, Germany).

Statistical analysis

All statistical analyses were performed with R (version 3.2.3). Continuous variables were reported as median and interquartile range (IQR), categorical variables as absolute numbers.
and frequencies (%). Statistical testing was performed with two-sided tests, p-values < 0.05 were considered significant. Wilcoxon rank-sum test was used for comparison of continuous variables between two groups, whereas Wilcoxon matched-pairs signed-rank test was applied for pairwise comparisons. Categorical variables were compared with Fisher’s exact test. For investigation of linear relationships between two variables linear regression was used.

Results

Patients’ characteristics

A total of 140 consecutive patients, 70 kidney and 70 liver transplant recipients, were included in this study. Baseline characteristics are shown in Table 1.

Kidney recipients. 70 kidney transplant recipients, 60% (n = 42) males, with a median age of 51 years participated in the study (Table 1). Most common causes of chronic renal failure were glomerulonephritis (n = 16, 22.9%), polycystic kidney disease (n = 12, 17.1%), nephrosclerosis (n = 11, 15.7%) and diabetic nephropathy (n = 7, 10%). Cadaveric renal grafts were used in 32 (45.7%) recipients, whereas 38 (54.3%) participants received grafts derived from living donation.

Liver recipients. Median age of the enrolled 70 liver recipients was 55 years, 67% (n = 47) were male (Table 1). The majority of liver transplantations was due to chemical cirrhosis (n = 18, 25.7%), hepatocellular carcinoma (n = 12, 17.1%), hepatitis C (n = 10, 14.3%) and hepatitis B (n = 7, 10%). Most participants were transplanted with cadaveric grafts (n = 64, 91.4%).

25-OH vitamin D and 1, 25-(OH)₂ vitamin D

Kidney recipients. At time of transplantation the majority of kidney recipients was severely vitamin D deficient (25-OHD < 25 nmol/l; n = 25, 35.7%) or vitamin D deficient (25-OHD ≥ 25 and < 50 nmol/l; n = 26, 37.1%). Vitamin D levels of at least 50 nmol/l were less frequent (n = 19, 27.1%) (Fig 1). Peri-transplant median 1, 25-(OH)₂D was 9.1 ng/l (IQR 7.5–13.8) (Table 2).

At 6 months post-transplant the number of severely vitamin D deficient patients dropped (n = 12, 17.1%), but vitamin D deficiency remained common (n = 34, 48.6%) (Fig 1). No vitamin D deficiency was measured in 23 (32.8%) participants (1 measurement failed). Six months after transplantation 25-OHD levels were ≥ 50 nmol/l in 37.3% of patients receiving supplementation therapy with a median dose of 800IU/d (vs. 0% in kidney recipients without supplementation therapy). No significant difference in 25-OHD levels between time of transplantation (median 32.5 nmol/l, IQR 18.0–52.0) and 6 months post-transplant (median 41.9 nmol/l, IQR 27.2–53.7) was detected (P = 0.272) (Fig 2). 6 months post-transplant 1, 25-(OH)₂D (median 36.5 ng/l, IQR 24.9–48.1) was significantly higher than peri-transplant (P<0.001) (Table 2).

The ratio of the active hormone 1, 25-(OH)₂D to its inactive precursor 25-OHD increased from peri-transplant (median 0.35 ng/nmol, IQR 0.19–0.69) to 6 months post-transplant (median 0.87 ng/nmol, IQR 0.67–1.36; P<0.001).

Liver recipients. In most liver transplant recipients severely deficient (n = 33, 47.1%) or deficient (n = 20, 28.6%) 25-OHD levels were detected at time of transplantation (Fig 1). A minor proportion of liver recipients showed no vitamin D deficiency (n = 17, 24.3%). Median 1, 25-(OH)₂D was 25.9 nmol/l (IQR 14.8–34.7) peri-transplant (Table 2).

Six months after transplantation the majority of liver recipients had severe 25-OHD deficiency (n = 27, 38.6%) or deficiency (n = 23, 32.9%). 25-OHD levels of at least 50nmol/l were detected in 20 patients (28.5%) (Fig 1). No vitamin D deficiency was detected in 36.7% of liver recipients with supplementation therapy (median dose 800IU/d) and 23.1% without...
Table 1. Baseline characteristics.

|                                | kidney (n = 70) | liver (n = 70) |
|--------------------------------|----------------|---------------|
| **Age median (IQR)**           | 52y (39, 62)   | 55y (43, 62)  |
| **Sex**                        |                |               |
| Male                           | 42 (60%)       | Male 47 (67%) |
| Female                         | 28 (40%)       | Female 23 (33%) |
| Premenopausal                  | 20             | Premenopausal 15 |
| Postmenopausal                 | 8              | Postmenopausal 8 |
| **Ethnicity**                  |                |               |
| Caucasian                      | 62 (88.6%)     | Caucasian 69 (98.6%) |
| African                        | 4 (5.7%)       | African 1 (1.4%) |
| Asian                          | 3 (4.3%)       |               |
| American Indian                | 1 (1.4%)       |               |
| **Underlying disease**         |                |               |
| Glomerulonephritis             | 16 (22.9%)     | Chemical cirrhosis 18 (25.7%) |
| Polycystic kidney disease      | 12 (17.1%)     | Hepatocellular carcinoma 12 (17.1%) |
| Nephrosclerosis                | 11 (15.7%)     | Hepatitis C 10 (14.3%) |
| Diabetic nephropathy           | 7 (10%)        | Hepatitis B 7 (10%) |
| Reflux nephropathy             | 4 (5.7%)       | Cholangiocarcinoma 4 (5.7%) |
| Other                          | 20 (28.6%)     | Other 19 (27.1%) |
| **Diabetes mellitus**          | 24 (34.3%)     | 29 (41.4%)    |
| **Renal replacement therapy**  |                |               |
| HD:                            | 43 (61.4%)     |               |
| PD:                            | 16 (22.9%)     |               |
| None:                          | 11 (15.7%)     |               |
| **Hepatorenal syndrome**       |                |               |
| present, no RRT                | 9 (12.9%)      |               |
| present, RRT                   | 6 (8.6%)       |               |
| absent, no RRT                 | 51 (72.9%)     |               |
| unknown                        | 4 (5.7%)       |               |
| **Type of donation**           | DBD 32 (45.7%) | DBD 64 (91.4%) |
| living related                 | 19 (27.2%)     | living related 5 (7.1%) |
| living unrelated               | 19 (27.2%)     | living unrelated 1 (1.4%) |
| **Type of transplant**         | Whole liver 65 (92.9%) | Split right 5 (7.1%) |
| **Corticosteroid-containing**  | Yes 62 (88.6%) | Yes 37(52.9%) |
| **immunosuppression**          | No  8 (11.4%)  | No 33 (47.1%) |
| **Vitamin D supplementation**  | peri-transplant | peri-transplant |
| cholecalciferol 26 (37.1%)     | cholecalciferol 8 (11.4%) |
| 1, 25-dihydroxycholecalciferol 25 (35.7%) | 1, 25-dihydroxycholecalciferol 2 (2.9%) |
| paricalcitol 1 (1.4%)          | paricalcitol 1 (1.4%) |
| 6 months post-transplant       | 6 months post-transplant |
| cholecalciferol 49/70 (70.0%)  | cholecalciferol 29 (41.4%) |
| 1, 25-dihydroxycholecalciferol 4 (5.7%) | 1, 25-dihydroxycholecalciferol 1 (1.4%) |
| **Calcium supplementation**    | peri-transplant | peri-transplant |
| Yes 53 (75.7%)                 | Yes 8 (11.4%)  |
| 6 months post-transplant       | 6 months post-transplant |
| Yes 42 (60.0%)                 | Yes 32 (45.7%) |

* Age-based assignment: <55y premenopausal, ≥55y postmenopausal
** Diagnosis of Diabetes mellitus either already established at time of transplantation or within the first 6 months after transplantation
*at 6 months post-transplant
**1 individual receiving supplementation with cholecalciferol and 1, 25-dihydroxycholecalciferol
***2 individuals receiving supplementation with cholecalciferol and 1, 25-dihydroxycholecalciferol
*Median dose of cholecalciferol 800IU (IQR 600–800), median dose of 1, 25-dihydroxycholecalciferol 0.25μg (IQR 0.25–0.25 μg)
**Median dose of calcium 1000mg (IQR 806–1200)
Abbreviations: DBD: donation after brain death, HD: hemodialysis, IQR: interquartile range, PD: peritoneal dialysis, RRT: renal replacement therapy

https://doi.org/10.1371/journal.pone.0191167.t001
supplementation therapy. 25-OHD levels remained stable between measurement peri- and 6 months post-transplant \((P = 0.414)\) (Fig 2). Six months post-transplant 1, 25-\((\mathrm{OH})_2\)D levels did not differ significantly from peri-transplant levels (median 29.7 nmol/l, IQR 18.7–40.7; \(P = 0.179\)) (Table 2). Similarly, no significant difference in the ratio of 1, 25-\((\mathrm{OH})_2\)D to 25-OHD was detectable between measurement peri-transplant (median 0.88 ng/nmol, IQR 0.58–1.53) and 6 months post-transplant (median 0.85 ng/nmol, IQR 0.60–1.41; \(P = 0.603\)).

**Estimated glomerular filtration rate, phosphate, intact parathyroid hormone, \(\beta\)-Crosslaps and total procollagen type 1 amino-terminal propeptide**

**Kidney recipients.** At time of transplantation median eGFR was 7.6 ml/min/1.73m\(^2\) (IQR 5.7–10.6); 6 months post-transplant eGFR was remarkably improved (median 54.1 ml/min/1.73m\(^2\), IQR 39.3–69.6) indicating excretory function of the kidney graft \((P<0.001)\) (Table 2). Phosphate levels decreased from 1.48 (IQR 1.19–1.87) to 0.6 mmol/l (IQR 0.68–1.09) in the longitudinal course \((P<0.001)\). Median iPTH was 208.7 ng/l (IQR 109.7–338.8) peri-transplant and dropped significantly to a median of 66.0 ng/l (IQR 49.2–102.7) 6 months post-
transplant ($P<0.001$). CTx levels, reflecting bone resorption, measured peri-transplant (median 1.32 ng/ml, IQR 0.60–2.01) were significantly higher than 6 months post-transplant (median 0.46 ng/ml, IQR 0.20–0.82; $P<0.001$). Similarly, P1NP values decreased from peri-transplant (median 158.2 ng/ml, IQR 93.9–310.8) to 6 months post-transplant (median 62.3 ng/ml, IQR 32.9–105.5; $P<0.001$). CTx and P1NP were positively correlated at time of transplantation ($R^2=0.46$, $P<0.001$) as well as 6 months post-transplant ($R^2=0.38$, $P<0.001$) (S1 Fig). Similarly, CTx and iPTH showed a linear relationship peri-transplant ($R^2=0.13$, $P=0.002$) and 6 months post-transplant ($R^2=0.30$, $P<0.001$) (S2 Fig).

Liver recipients. Estimated glomerular filtration rate showed a significant decrease from peri-transplant (median 89.1 ml/min/1.73m$^2$, IQR 55.3–108.9) to 6 months post-transplant (median 65.5 ml/min/1.73m$^2$, IQR 53.0–84.3; $P=0.011$) (Table 2). Median phosphate was 1.06 mmol/l (IQR 0.86–1.34) at time of transplantation and increased to 1.21 mmol/l (1.09–1.39) at 6 months post-transplant ($P=0.006$). No remarkable difference was observed between

Table 2. Measurement of 25-OHD, 1, 25-(OH)$_2$D, 1, 25-(OH)$_2$D/25OHHD ratio, iPTH, CTx, P1NP, creatinine and phosphate peri-transplant and 6 months post-transplant.

|                | peri-transplant | 6 months post-TPL | $P^*$ |
|----------------|-----------------|-------------------|-------|
| kidney         |                 |                   |       |
| 25-OHD         | n = 70          | n = 70            |       |
| 32.5 (18.0–52.0) | 41.9 (27.2–53.7) | 0.272             |       |
| 1, 25-(OH)$_2$D| 9.1 (7.5–13.8)  | 36.5 (24.9–48.1)  | <0.001|
| 1, 25-(OH)$_2$D/25-OHD | 0.35 (0.19–0.69) | 0.87 (0.67–1.36)  | <0.001|
| iPTH           | 208.7 (109.7–338.8) | 66.0 (49.2–102.7) | <0.001|
| CTx            | 1.32 (0.60–2.01) | 0.46 (0.20–0.82)  | <0.001|
| P1NP           | 158.2 (93.9–310.8) | 62.3 (32.9–105.5) | <0.001|
| creatinine     | 646.0 (491.2–782.8) | 116.5 (102.0–157.5) | <0.001|
| eGFR           | 7.6 (5.7–10.6)  | 54.1 (39.3–69.6)  | <0.001|
| phosphate      | 1.48 (1.19–1.87) | 0.86 (0.68–1.09)  | <0.001|
| liver          |                 |                   |       |
| 25-OHD         | n = 70          | n = 70            |       |
| 28.0 (13.1–48.8) | 32.3 (17.7–54.1) | 0.414             |       |
| 1, 25-(OH)$_2$D| 25.9 (14.8–34.7) | 29.7 (18.7–40.7)  | 0.179             |       |
| 1, 25-(OH)$_2$D/25-OHD | 0.88 (0.58–1.53) | 0.85 (0.60–1.41)  | 0.603             |       |
| iPTH           | 34.7 (22.6–61.7) | 44.9 (35.5–60.6)  | 0.107             |       |
| CTx            | 0.45 (0.25–0.81) | 0.72 (0.47–1.03)  | 0.002             |       |
| P1NP           | 84.0 (53.9–146.4) | 125.4 (67.0–200.5) | 0.001             |       |
| creatinine     | 77.0 (62.5–116.5) | 99.5 (80.5–130.0)  | 0.005             |       |
| eGFR           | 89.1 (55.3–108.9) | 65.5 (53.0–84.3)  | 0.011             |       |
| phosphate      | 1.06 (0.86–1.34) | 1.21 (1.09–1.59)  | 0.006             |       |

Numeric variables expressed as median (IQR).
25-OHD (25-OH vitamin D) reported in nmol/l
1, 25-(OH)$_2$D (1, 25-(OH)$_2$ vitamin D) reported in ng/l
1, 25-(OH)$_2$D/25OHHD ratio in ng/nmol
iPTH (intact parathyroid hormone) reported in ng/l
CTx (β-Crosslaps) reported in ng/ml
P1NP (total procollagen type 1 amino-terminal propeptide) reported in ng/ml
Creatinine reported in μmol/l
eGFR (estimated glomerular filtration rate) reported in ml/min/1.73m$^2$ (calculated according to CKD-EPI)
Phosphate reported in mmol/l
* Wilcoxon matched-pairs signed-rank test was used for comparison.

https://doi.org/10.1371/journal.pone.0191167.1002
peri-transplant and 6 months post-transplant iPTH levels. Peri-transplant CTx levels were significantly lower (median 0.45 ng/ml, IQR 0.25–0.81) than 6 months post-transplant (median 0.72 ng/ml, IQR 0.47–1.03; \( P = 0.002 \)). P1NP levels also increased between measurement peri-transplant (median 84.0 ng/ml, IQR 53.9–146.4) and 6 months post-transplant (median 125.4 ng/ml, IQR 67.0–200.5; \( P = 0.001 \)). Like in kidney transplantation, a positive correlation between CTx and P1NP (peri-transplant \( R^2 = 0.25, P<0.001 \); 6 months post-transplant \( R^2 = 0.46, P<0.001 \) (S1 Fig) as well as between CTx and iPTH (peri-transplant \( R^2 = 0.21, P<0.001 \); 6 months post-transplant \( R^2 = 0.24, P<0.001 \) (S2 Fig) was detectable.

Fig 2. Longitudinal changes in 25-OH vitamin D, 1, 25-(OH)_2 vitamin D, intact parathyroid hormone, \( \beta \)-Crosslaps, total procollagen type 1 amino-terminal propeptide, estimated glomerular filtration rate, phosphate in the first 6 months after kidney and liver transplantation. Arrows pointing upwards indicate significant increase, arrows pointing downwards indicate significant decrease, horizontal arrows respond to no significant changes. 25-OHD: 25-OH vitamin D, 1, 25-(OH)_2 D: 1, 25-(OH)_2 vitamin D, iPTH: intact parathyroid hormone, CTx: \( \beta \)-Crosslaps, P1NP: total procollagen type 1 amino-terminal propeptide.

https://doi.org/10.1371/journal.pone.0191167.g002
Incident fractures and bone densitometry

**Kidney recipients.** Overall 7 fractures occurred in a total of 7 kidney recipients (corresponding to an incidence of 16 fractures per 1000 person-years); 4 (57.1%) fractures affected the lower extremities, 2 (28.6%) the upper extremities and 1 (14.3%) the spine. The median time interval from transplantation to fracture was 866 days (IQR 352–1368). Kidney recipients with incident fractures had lower 1, 25-(OH)₂D levels peri-transplant ($P = 0.008$) (Table 3). Likely, 6 months post-transplant 1, 25-(OH)₂D tended to be higher in kidney recipients without incident fractures ($P = 0.089$). Patients suffering from incident fractures showed a marginally significantly better eGFR ($P = 0.049$) at time of transplantation, lower iPTH levels ($P = 0.008$) and a trend of lower CTx levels ($P = 0.064$) 6 months after transplantation. BMI tended to be higher in patients without incident fractures ($P = 0.054$). In 36 of 70 kidney recipients DXA scans were available. As bone densitometry was performed by the treating physician's indication, a large variety in timespan from transplant to bone densitometry was observed (median 242 days, IQR 57–742). Osteoporosis, defined by a T-score of less than -2.5 at any location, was present in 9 (25%) and osteopenia (T-score $\geq -2.5$ and $<-1$) in 20 (55.6%) individuals, whereas only 7 (19.4%) kidney transplant recipients had normal BMD. Notably, an increasing timespan until DXA scan was associated with a linear decrease in the T-score of the femoral neck ($R^2 = 0.14$, $P = 0.027$) (Fig 3). In 5 individuals with incident fractures bone densitometry was available. Fractures were recorded in 1 patient with osteoporosis, 3 patients with osteopenia and 1 patient with normal BMD.

**Liver recipients.** In 9 liver recipients fractures were observed, equaling an incidence of 23 fractures per 1000 person-years. Vertebral fractures were most common (n = 6, 66.7%), followed by 2 (22.2%) fractures of the upper extremities and 1 (11.1%) fracture of the lower extremities. Fractures occurred after a median of 274 days (IQR 171–661) following liver transplantation. Liver recipients with incident fractures were older ($P = 0.004$), but no significant differences were detected in BMI, diabetes mellitus, use of steroids for immunosuppression, phosphate levels and the assessed panel of biomarkers (Table 3). In 18 liver recipients BMD measurements were performed after transplantation. Normal BMD was detected in 5 (27.8%) liver transplant recipients, whereas in 11 (61.1%) and 2 (11.1%) patients osteopenia and osteoporosis were diagnosed, respectively. In 3 patients with incident fractures DXA scans were performed. 2 patients suffering from vertebral fractures had osteoporosis and 1 patient with vertebral fracture osteopenia.

**Discussion**

In both, kidney and liver recipients, 25-OH vitamin D remained on similar levels within the first 6 months post-transplant, whereas 1, 25-(OH)₂D was significantly higher 6 months post-transplant in kidney recipients, but not in liver recipients. Levels of iPTH dropped in kidney recipients, but stayed unchanged in liver recipients. The bone turnover markers CTx and P1NP showed a significant decrease in kidney transplant recipients and on the contrary a significant increase in liver transplant recipients within the first 6 months after transplantation.

Parallel to the excretory renal function an improvement of the hormonal capacity of the transplant was observed after kidney transplantation, indicated by the increased ratio of 1, 25-(OH)₂D to 25-OHD 6 months post-transplant. The low level of 1, 25-(OH)₂D might be also partly due to the assumed premenopausal status of most kidney transplant recipients shown in a subgroup analysis (S2 Table). The high peri-transplant iPTH levels, reflecting most likely secondary hyperparathyroidism in the majority of kidney recipients, decreased to significantly lower levels 6 months post-transplant. In kidney transplant recipients, elevated peri-transplant levels of CTx and P1NP indicated simultaneous ongoing bone formation and bone resorption.
Table 3. Comparison between kidney recipients and liver recipients with incident fractures and without fractures, respectively.

|                        | Fracture | Non-fracture | P* |
|------------------------|----------|--------------|----|
| kidney                 | n = 7    | n = 63       |    |
| Sex (male)             | 3 (42.9%)| 39 (61.9%)   | 0.426|
| Age                    | 48.4 (43.6–54.7) | 52.7 (38.4–62.2) | 0.984|
| BMI                    | 19.7 (18.5–25.1) | 24.7 (22.8–27.6) | 0.054|
| Steroid containing immunosuppressive regimen | 7 (100%) | 55 (87.3%) | 1 |
| Diabetes mellitus      | 2 (28.6%)| 22 (34.9%)   | 1  |
| 25-OHD peri-transplant  | 30.0 (13.7–37.2) | 34.4 (18.7–52.9) | 0.318|
| 25-OHD 6 months post-transplant | 56.7 (44.3–61.7) | 41.2 (27.2–52.7) | 0.176|
| 1, 25-(OH)2D peri-transplant | < 7.5* | 9.3 (7.5–14.6) | 0.008|
| 1, 25-(OH)2D 6 months post-transplant | 26.0 (17.2–30.6) | 38.1 (25.7–48.3) | 0.089|
| iPTH peri-transplant   | 115.8 (111.3–170.0) | 216.2 (108.8–351.8) | 0.248|
| iPTH 6 months post-transplant | 42.6 (38.1–46.5) | 69.7 (54.6–106.2) | 0.008|
| CTx peri-transplant    | 0.58 (0.52–1.64) | 1.44 (0.68–2.01) | 0.225|
| CTx 6 months post-transplant | 0.30 (0.13–0.40) | 0.52 (0.23–0.85) | 0.064|
| P1NP peri-transplant   | 113.0 (48.1–263.0) | 165.3 (94.4–317.9) | 0.253|
| P1NP 6 months post-transplant | 56.3 (45.7–86.6) | 63.1 (32.4–108.7) | 0.741|
| eGFR peri-transplant   | 30.1 (26.7–33.5) | 50.0 (38.1–79.1) | 0.298|
| eGFR 6 months post-transplant | 29.2 (14.0–62.9) | 33.0 (17.7–53.9) | 0.874|
| Phosphate peri-transplant | 1.57 (1.09–2.26) | 1.48 (1.20–1.84) | 0.611|
| Phosphate 6 months post-transplant | 0.91 (0.679–1.04) | 0.83 (0.67–1.09) | 0.611|
| Liver                  | n = 9    | n = 61       |    |
| Sex (male)             | 6 (66.7%)| 41 (67.2%)   | 1  |
| Age                    | 64.5 (58.6–68.7) | 54.2 (44.0–60.1) | 0.004|
| BMI                    | 24.1 (22.4–26.0) | 24.6 (21.5–26.0) | 0.979|
| Steroid containing immunosuppressive regimen | 7 (77.8%) | 30 (49.2%) | 0.157|
| Diabetes mellitus      | 5 (55.6%)| 23 (37.7%)   | 0.468|
| 25-OHD peri-transplant  | 23.5 (12.7–33.5) | 29.0 (14.2–53.7) | 0.499|
| 25-OHD 6 months post-transplant | 29.2 (14.0–62.9) | 33.0 (17.7–53.9) | 0.874|
| 1, 25-(OH)2D peri-transplant | 22.8 (9.4–30.1) | 26.0 (15.5–35.9) | 0.182|
| 1, 25-(OH)2D 6 months post-transplant | 21.6 (18.7–36.8) | 30.0 (20.1–40.8) | 0.330|
| iPTH peri-transplant   | 29.4 (16.6–103.8) | 36.0 (22.7–59.2) | 0.986|
| iPTH 6 months post-transplant | 35.9 (26.2–43.4) | 46.2 (36.5–64.1) | 0.112|
| CTx peri-transplant    | 0.50 (0.30–1.50) | 0.44 (0.24–0.74) | 0.317|
| CTx 6 months post-transplant | 0.78 (0.58–1.04) | 0.72 (0.45–1.02) | 0.467|
| P1NP peri-transplant   | 95.3 (92.6–186.2) | 71.9 (53.6–127.1) | 0.277|
| P1NP 6 months post-transplant | 132.9 (65.7–185.6) | 125.0 (70.2–204.0) | 0.930|
| eGFR peri-transplant   | 55.9 (15.4–101.2) | 89.5 (61.3–109.1) | 0.125|
| eGFR 6 months post-transplant | 63.9 (34.0–71.2) | 67.9 (53.4–86.8) | 0.335|
| Phosphate peri-transplant | 1.25 (1.00–1.34) | 1.05 (0.86–1.33) | 0.397|
| Phosphate 6 months post-transplant | 1.18 (1.18–1.36) | 1.21 (1.09–1.39) | 0.759|

Numeric variables expressed as median (IQR), categorical variables as absolute numbers (frequencies).

Age reported in years
BMI (body mass index) reported in kg/m²
25-OHD (25-OH vitamin D) reported in nmol/l
1, 25-(OH)2D (1, 25-(OH)2 vitamin D) reported in ng/l
iPTH (intact parathyroid hormone) reported in ng/l
CTx (β-Crosslaps) reported in ng/ml
P1NP (total procollagen type 1 amino-terminal propeptide) reported in ng/ml

*Immunosuppressive regimen assessed 6 months after transplantation.
* lower detection limit 7.5ng/l
* Fisher’s exact test and Wilcoxon rank-sum test were used for comparison, as appropriate.

https://doi.org/10.1371/journal.pone.0191167.t003
These contrarious processes were occurring simultaneously as indicated by the significant correlation between CTx and P1NP. The parallel elevation of these bone turnover markers at time of transplantation might reflect a state of high bone turnover, such as osteitis fibrosa, or might be, at least partly, caused by a diminished renal excretion of CTx and accumulation of the monomeric form of P1NP [24, 25]. In agreement with our data, a linear relationship between CTx and P1NP was described by Ueda et al for hemodialysis patients [26].

The considerable increase in both, CTx and P1NP, at 6 months post-transplant in liver recipients is indicative of a high bone turnover state. The reasons for these changes in bone metabolism are unclear. One explanation may be a combined effect of vitamin D deficiency, triggering an overall, albeit not significant, increase in iPTH, and deterioration of kidney function, possibly due to calcineurin-inhibitor toxicity, thus promoting incipient renal osteodystrophy. This hypothesis would be supported by the significant decrease in eGFR of liver recipients. Alternatively, the change in eGFR might be influenced by a gain in muscle mass post-transplant.

The longitudinal development of the assessed biomarkers showed major differences between kidney and liver transplant recipients in 1, 25-(OH)₂ vitamin D, iPTH, CTx, P1NP, eGFR and phosphate levels. In kidney transplant recipients the increase in 1-position hydroxylation of vitamin D was to be expected as the decrease in iPTH due to hormonal activity of the graft. Likely, the improvement in eGFR and decrease in phosphate reflects exocrine renal function of the kidney graft. With regard to the hormonal function of the liver an increase in
25-OH vitamin D would be assumed. The avoidance of sun exposure resulting in a shortage of the precursor hormone vitamin D might be a possible explanation for the unchanged 25-OH vitamin D levels after liver transplantation. The observed decline in eGFR after liver transplantation has been reported before [27] and might be multifactorial as discussed above.

Bone turnover markers are rarely measured in clinical routine. Determination of CTx and P1NP has been encouraged as a monitoring tool in patients treated for various bone disorders [28, 29]. Previous studies have demonstrated a correlation of CTx with biopsy-proven bone resorption [30]. A further application of bone turnover markers includes cancer patients, where CTx has been shown to be a marker of bone metastases [31] and of bone involvement in multiple myeloma [32]. Beyond determination of vitamin D metabolites, iPTH and markers of bone metabolism our study adds a translational aspect characterizing the association of these markers with the most relevant clinical endpoint, i.e. incidence of fractures.

All reported fractures in our study were diagnosed by radiographs prompted by symptoms. 12.9% of liver recipients suffered from fractures. Previously published data on fracture incidence after liver transplantation show a wide variability [11, 33–38]. This imprecision might be caused by differences in diagnostic assessment (radiographs per protocol vs. radiographs triggered by symptoms), different lengths of patient follow up as well as temporal changes in immunosuppression with recent strategies favoring early steroid withdrawal. In our study liver graft recipients suffering from fractures were significantly older than recipients without fractures. This finding is in line with previous studies [11, 36].

Similar to liver transplantation, literature on fracture rates after kidney transplantation is characterized by a large variety [39]. Studies with longer observation periods indicated overall a higher fracture rate [40, 41]. We recorded fractures in 10% of kidney recipients over a median follow-up of 5.6 years. Consistent with literature most fractures in kidney recipients affected the appendicular skeleton and, in particular, the lower extremities [12, 42]. In kidney graft recipients with incident fractures 1, 25-(OH)₂D levels were significantly lower peri-transplant, this observation waned to a trend at 6 months post-transplant. This finding highlights the importance of the biologically active vitamin D metabolite for bone health. Higher levels of iPTH and a trend of higher CTx were found in kidney recipients without incident fractures 6 months post-transplant, but not at time of transplantation. This observation might indicate that a certain level of bone resorption needs to be maintained for bone health. A longer time-span between kidney transplantation and BMD measurement showed a negative linear relationship with the T-score of the femoral neck. Time-dependent deleterious effects of immunosuppression might be at the cause of this observation. Immunosuppressive agents have been associated with abnormal bone composition. This harmful effect is best established for corticosteroids which have been linked to both, osteoporosis and fractures [43, 44]. Of note, in our study all kidney transplant recipients with incident fractures received a steroid-containing immunosuppressive regimen at least until 6 months post-transplant (vs. 87.3% of patients without incident fractures). The impact of other immunosuppressive agents on bone metabolism is less clear, e.g. conflicting results have been reported for cyclosporine A [45–47].

One main strength of our study lies in the longitudinal, uniform measurement of key variables involved in bone metabolism, including vitamin D metabolites, iPTH and the bone turnover markers CTx and P1NP, utilizing samples derived from time of transplant and 6 months after transplantation. The multicenter cohort design with participation of all Swiss transplant centers minimizes the impact of center-specific differences in post-transplant patient care.

Our study has several limitations. First, data on DXA scans and incident fractures were retrospectively collected. Second, BMD measurements were performed at the discretion of the treating physician and not according to a protocol. All analyzed DXA scans were performed post-transplant, different devices were used and scans were done at varying time points post-
transplant, but timespan since transplantation is likely a crucial factor for bone loss. Baseline BMD at time of transplantation was not assessed, thus we might have missed preexisting abnormal BMD. Third, radiographs were exclusively taken, if clinically indicated, i.e. suspicion of a fracture. This approach inevitably results in missing asymptomatic fractures.

In conclusion, our data illustrates substantial alterations of bone metabolism markers in the first 6 months after transplantation. Hallmarks were a significant gain in 1,25-(OH)₂D combined with a decrease in iPPTH, CTx and P1NP after kidney transplantation and an increase in CTx and P1NP after liver transplantation.

Future studies with longitudinal measurement of a comprehensive bone metabolism panel, including CTx and P1NP, combined with serial DXA scans could help to gain a more precise insight into the role of bone turnover markers in the transplant population.

**Supporting information**

**S1 Table.** Reference values and coefficients of variation for used laboratory assays.

(DOCX)

**S2 Table.** Comparison of vitamin D metabolites, iPPTH, CTx, P1NP and phosphate between pre- and postmenopausal female transplant recipients.

(DOCX)

**S1 Fig.** Correlation of CTx and P1NP in kidney recipients and liver recipients. Line was generated corresponding to univariable linear regression.

(TIF)

**S2 Fig.** Correlation of CTx and iPPTH in kidney recipients and liver recipients. Line was generated corresponding to univariable linear regression.

(TIF)

**Acknowledgments**

The authors thank all patients for their willingness to participate in the STCS. PWS especially acknowledges Alex Marzel, Mohaned Shliah and Alexandra Scherrer for their support in data analysis and critical comments.

This study has been conducted in the framework of the Swiss Transplant Cohort Study. The members of the Swiss Transplant Cohort Study are: Rita Achermann, John-David Aubert, Philippe Baumann, Guido Beldi, Christian Benden, Christoph Berger, Isabelle Binet, Pierre-Yves Bochud, Elsa Boely (Head of local data management), Heiner Bucher, Leo Bühler, Thierry Carell, Emmanuelle Catana, Yves Chalandon, Sabina de Geest, Olivier de Rougemont, Michael Dickenmann, Michel Duchosal, Thomas Fehr, Sylvie Ferrari-Lacraz, Christian Garzoni, Yvan Gasche, Paola Gasche Soccal, Emiliano Giostra, Délia Golshayan, Daniel Good, Karine Hadaya, Christoph Hess, Sven Hillinger, Hans H. Hirsch, Günther Hofbauer, Uyen Huynh-Do, Franz Immer, Richard Klaghofer, Michael Koller (Head of the data center), Thomas Kuntzen, Bettina Laesser, Roger Lehmann, Christian Lovis, Oriol Manuel, Hans-Peter Marti, Pierre Yves Martin, Pascal Meylan (Head, Biological samples management group), Paul Mohacsi, Isabelle Morard, Philippe Morel, Ulrike Mueller, Nicolas J Mueller (Chairman Scientific Committee), Helen Mueller-McKenna, Thomas Müller, Beat Müllerhaupt, David Nadal, Gayathri Nair, Manuel Pascual (Executive office), Jakob Passweg, Chantal Piot Ziegler, Juliane Rick, Eddy Roosnek, Anne Rosselet, Silvia Rothlin, Frank Ruschitzka, Urs Schanz, Stefan Schaub, Christian Seiler, Nasser Semmo, Susanne Stampf, Jürg Steiger (Head, Executive Office), Christian Toso, Dimitri Tsinalis, Christian Van Delden (Executive office),
Jean-Pierre Venetz, Jean Villard, Madeleine Wick (STCS coordinator), Markus Wilhelm, Patrick Yerly.

**Author Contributions**

**Conceptualization:** Peter W. Schreiber, Heike A. Bischoff-Ferrari, Marco Bonani, Thomas Fehr, Nicolas J. Mueller.

**Data curation:** Peter W. Schreiber, Nicolas J. Mueller.

**Formal analysis:** Peter W. Schreiber, Heike A. Bischoff-Ferrari, Marco Bonani.

**Funding acquisition:** Peter W. Schreiber, Thomas Fehr, Nicolas J. Mueller.

**Investigation:** Peter W. Schreiber, Katia Boggian, Christian van Delden, Natalia Enriquez, Christian Garzoni, Hans H. Hirsch, Cédric Hirzel, Oriol Manuel, Pascal Meylan, Lanja Saleh, Maja Weisser, Nicolas J. Mueller.

**Methodology:** Peter W. Schreiber, Marco Bonani, Thomas Fehr, Nicolas J. Mueller.

**Project administration:** Nicolas J. Mueller.

**Resources:** Katia Boggian, Christian van Delden, Natalia Enriquez, Christian Garzoni, Hans H. Hirsch, Cédric Hirzel, Oriol Manuel, Pascal Meylan, Lanja Saleh, Maja Weisser, Nicolas J. Mueller.

**Software:** Peter W. Schreiber.

**Supervision:** Nicolas J. Mueller.

**Validation:** Peter W. Schreiber, Heike A. Bischoff-Ferrari, Thomas Fehr, Lanja Saleh, Nicolas J. Mueller.

**Writing – original draft:** Peter W. Schreiber, Nicolas J. Mueller.

**Writing – review & editing:** Peter W. Schreiber, Heike A. Bischoff-Ferrari, Katia Boggian, Marco Bonani, Christian van Delden, Natalia Enriquez, Thomas Fehr, Christian Garzoni, Hans H. Hirsch, Cédric Hirzel, Oriol Manuel, Pascal Meylan, Lanja Saleh, Maja Weisser, Nicolas J. Mueller.

**References**

1. Network Organ Procurement and Transplantation. National Data: U.S. Department of Health & Human Services; 2017 [cited 2017 22.02.2017]. https://optn.transplant.hrsa.gov/data/view-data-reports.

2. Monegal A, Navasa M, Peris P, Colmenero J, Cuervo A, Muxi A, et al. Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades? Calcified tissue international. 2013; 93(6):571–6. Epub 2013/09/26. https://doi.org/10.1007/s00223-013-9797-4 PMID: 24065305.

3. Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Seminars in dialysis. 2007; 20(5):423–30. Epub 2007/09/28. https://doi.org/10.1111/j.1525-139X.2007.00319.x PMID: 17897249.

4. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcified tissue international. 2001; 69(6):321–6. Epub 2002/01/22. PMID: 11800228.

5. Bang UC, Benfield T, Bendtsen F, Hylstrup L, Beck Jensen JE. The risk of fractures among patients with cirrhosis or chronic pancreatitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2014; 12(2):320–6. Epub 2013/05/07. https://doi.org/10.1016/j.cgh.2013.04.031 PMID: 23644391.

6. Ruiz-Gaspa S, Martinez-Ferrer A, Guanabens N, Dubreuil M, Peris P, Enjuanes A, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology (Baltimore, Md). 2011; 54(6):2104–13. Epub 2011/08/13. https://doi.org/10.1002/hep.24605 PMID: 21837749.
7. Floreani A, Mega A, Tizian L, Burra P, Boccaagni P, Baldo V, et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int. 2001; 12(9):749–54. Epub 2001/10/19. https://doi.org/10.1007/s001980170051 PMID: 11605741.

8. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology (Baltimore, Md). 1998; 28(3):695–9. Epub 1998/09/10. https://doi.org/10.1002/hep.510280315 PMID: 9731561.

9. Hruska KA, Teitelbaum SL. Renal osteodystrophy. The New England journal of medicine. 1995; 333(3):166–74. Epub 1995/07/20. https://doi.org/10.1056/NEJM199507203330307 PMID: 7791820.

10. Krol CG, Dekkers OM, Kroon HM, Rabelink TJ, van Hoek B, Hamdy NA. Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment. J Bone Miner Res. 2014; 29(8):1763–9. Epub 2014/03/20. https://doi.org/10.1002/jbmr.2214 PMID: 24644003.

11. Koller MT, van Delden C, Muller NJ, Baumann P, Lovis C, Marti HP, et al. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. European journal of epidemiology. 2013; 28(4):347–55. Epub 2013/04/03. https://doi.org/10.1007/s10654-012-9754-y PMID: 23546768.

12. Naylor KL, Jamal SA, Zou G, McArthur E, Lam NN, Leslie WD, et al. Fracture incidence in adult kidney transplant recipients. Transplantation. 2015. Epub 2015/07/15. https://doi.org/10.1097/tp.0000000000000808 PMID: 26154389.

13. Holick MF. Vitamin D deficiency. The New England journal of medicine. 2007; 357(3):266–81. Epub 2007/07/20. https://doi.org/10.1056/NEJMra070553 PMID: 17634462.

14. Bringhurst eaFR. Bone and Mineral Metabolism in Health and Disease. In: Dan L. Longo E, Fauci Anthony S., Editor editor. Harrison’s Principles of Internal Medicine, 18e. 18 edition (August 11, 2011): McGraw-Hill Professional; 2011.

15. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Annals of epidemiology. 2009; 19(2):73–8. Epub 2008/03/11. https://doi.org/10.1016/j.annepidem.2007.12.001 PMID: 18329892.

16. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiological reviews. 2016; 96(1):365–408. Epub 2015/12/19. https://doi.org/10.1152/physrev.00014.2015 PMID: 26681795.

17. Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. Journal of the American Society of Nephrology: JASN. 2011; 22(2):216–24. Epub 2010/12/18. https://doi.org/10.1681/ASN.2010020186 PMID: 21164021.

18. Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012; 8(7):379–89. Epub 2012/06/06. https://doi.org/10.1038/nrrheum.2012.86 PMID: 22664836.

19. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011; 49(8):1271–4. Epub 2011/05/25. https://doi.org/10.1515/CCLM.2011.602 PMID: 21605012.

20. Koller MT, van Delden C, Muller NJ, Baumann P, Lovis C, Marti HP, et al. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. European journal of epidemiology. 2013; 28(4):347–55. Epub 2013/04/03. https://doi.org/10.1007/s10654-012-9754-y PMID: 23546766.

21. Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, et al. Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. Maturitas. 2010; 67(1):60–6. Epub 2010/05/25. https://doi.org/10.1016/j.maturitas.2010.04.015 PMID: 20494530.

22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604–12. Epub 2009/05/06. PMID: 1914839.

23. Zitta S, Schaffellner S, Gutschl J, Meinitzer A, Kniepeiss D, Aringer K, et al. The Effect of Mammalian Target of Rapamycin Versus Calcineurin Inhibitor-based Immunosuppression on Measured Versus Estimated Glomerular Filtration Rate After Orthotopic Liver Transplantation. Transplantation. 2015; 99(6):1250–6. Epub 2015/01/22. PMID: 25606796.

24. Morris HA, Eastell R, Jorgensen NR, Cavalier E, Vasikaran S, Chubb SA, et al. Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clinica chimica acta; international journal of clinical chemistry. 2016. Epub 2016/07/05. https://doi.org/10.1016/j.cca.2016.06.036 PMID: 27374301.

25. Cavalier E, Lukas P, Carlisi A, Gadisseux R, Delanaye P. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clinica chimica acta; international
Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002; 40(4):802–9. Epub 2002/09/27. https://doi.org/10.1053/ajkd.2002.35692 PMID: 12324916.

Cohen AJ, Stegall MD, Rosen CB, Wiesner RH, Leung N, Kremers WK, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl. 2002; 8(10):916–21. Epub 2002/10/03. https://doi.org/10.1053/ljts.2002.35668 PMID: 12360433.

Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013; 11:201. Epub 2013/08/30. https://doi.org/10.1186/1479-5876-11-201 PMID: 23984630.

Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008; 12(3):157–70. Epub 2008/05/31. PMID: 18510379.

Chavassieux P, Portero-Muzny N, Roux JP, Garnero P, Chapurlat R. Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women? The Journal of clinical endocrinology and metabolism. 2015; 100(12):4662–8. Epub 2015/10/28. https://doi.org/10.1210/jc.2015-2957 PMID: 26505821.

Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia. 2010; 12(9):685–96. Epub 2010/09/09. PMID: 20824045.

Dizdar O, Barista I, Kalyoncu U, Karadag O, Hascelik G, Cila A, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol. 2007; 82(3):185–91. Epub 2006/10/06. https://doi.org/10.1002/ajh.20794 PMID: 17022050.

Hardinger KL, Ho B, Schnitzler MA, Desai N, Lowell J, Shenoy S, et al. Serial measurements of bone density at the lumbar spine do not predict fracture risk after liver transplantation. Liver Transpl. 2003; 9(8):857–62. Epub 2003/07/29. https://doi.org/10.1053/jlts.2003.50135 PMID: 12884200.

Premaor MO, Das TK, Debiram I, Parker RA, Ninkovic M, Alexander GT, et al. Fracture incidence after liver transplantation: results of a 10-year audit. QJM. 2011; 104(7):599–606. Epub 2011/03/10. https://doi.org/10.1093/qjmed/hcr025 PMID: 21385830.

Monegali A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001; 12(6):484–92. Epub 2001/07/12. https://doi.org/10.1007/s001980170094 PMID: 11446565.

Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001; 357(9253):342–7. Epub 2001/02/24. https://doi.org/10.1016/S0140-6736(00)03641-2 PMID: 112010996.

McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Shell AG, Evans RA, et al. Bone loss after liver transplantation. Hepatology (Baltim ore, Md). 1991; 14(4 Pt 1):613–9. Epub 1991/10/01. PMID: 1916662.

Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compton JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2000; 12(8):931–5. Epub 2000/08/25. PMID: 10958221.

Naylor KL, Li AH, Lam NN, Hodsmn AB, Jamal SA, Garg AX. Fracture risk in kidney transplant recipients: a systematic review. Transplantation. 2013; 95(12):1461–70. Epub 2013/04/19. PMID: 23594857.

Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N. Risk of fractures after renal transplantation in the United States. Transplantation. 2009; 87(12):1846–51. Epub 2009/06/23. https://doi.org/10.1097/TP.0b013e3181a6bbda PMID: 19543063.

Rizzardi MD, Suszyński TM, Gillingham KJ, Dunnn TB, Ibrahim HN, Payne WD, et al. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol. 2012; 7(3):493–503. Epub 2012/01/28. https://doi.org/10.2215/CJN.08630811 PMID: 22282482.

Bia M. Evaluation and management of bone disease and fractures post transplant. Transplant Rev (Orlando). 2008; 22(1):52–61. Epub 2008/07/18. https://doi.org/10.1016/j.trre.2007.09.001 PMID: 18631858.

Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6):993–1000. Epub 2000/06/07. https://doi.org/10.1359/jbmr.2000.15.6.993 PMID: 10841167.
44. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation. 1997; 63(3):380–6. Epub 1997/02/15. PMID: 9039927.

45. El Haggan W, Barthe N, Vendrely B, Chauveau P, Berger F, Aparicio M, et al. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. Transplant Proc. 2002; 34(5):1817–8. Epub 2002/08/15. PMID: 12176589.

46. Cueto-Manzano AM, Konel S, Crowley V, France MW, Freemont AJ, Adams JE, et al. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation. 2003; 75(12):2053–8. Epub 2003/06/28. https://doi.org/10.1097/01.TP.0000068869.21770.F6 PMID: 12829911.

47. Katz I, Li M, Joffe I, Stein B, Jacobs T, Liang XG, et al. Influence of age on cyclosporin A-induced alterations in bone mineral metabolism in the rat in vivo. J Bone Miner Res. 1994; 9(1):59–67. Epub 1994/01/01. https://doi.org/10.1002/jbmr.5650090109 PMID: 8154310.